Respiratory Disorders Treatment Market: Latest Industry Trends, Market Size, Market Share by Application and Regional Forecast 2022-2031

“The report on Respiratory Disorders Treatment Market was recently published by SDKI, which includes the latest market trends, current and future opportunities along with the factors that are driving the growth of the market. This report further encompasses the records for the expansion of the market along with information on the investment opportunities that help the clients to take positive decisions on the parameters for gaining profitable revenues. Moreover, the report also contains identification and investigation of the market structure, in-depth qualitative analysis, restraints & challenges, growth drivers, emerging product trends & market opportunities and Porter’s five forces.

Download Sample of This Strategic Report: https://www.sdki.us/sample-request-111020

Respiratory Disorders Treatment Market: Overview

  • According to the latest report on the respiratory disorders treatment market for the historical period 2022-2031 and forecast period 2022-2031, increase in incidence of respiratory disorders, surge in supportive care products to meet the rise in demand for treatment of respiratory disorders, entry of new players, and rise in access to healthcare are projected to drive the global respiratory disorders treatment market
  • According to the report, the global respiratory disorders treatment market was valued at ~US$ 64 Bn in 2018 and is anticipated to expand at a CAGR of ~6% from 2022-2031

Rise in Prevalence of Respiratory Disorders and Surge in Adoption of Combination Therapy: Key Drivers

  • Rise in focus on smart or digital inhalers for administration of asthma or COPD drugs drives the global respiratory disorders treatment market
  • Combination therapy includes LAMA-ICS and LABA-ICS. Adoption of combination therapy is increasing, as these are more effective than the separate use of bronchodilator and corticosteroid. Moreover, the number of patients being successfully treated with combination therapy has increased.
  • Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labor and Welfare (MHLW) have approved the use of combination drugs for the treatment of respiratory disorders such as asthma and COPD
  • According to the WHO, prevalence of allergic diseases in the developed world has increased significantly in the past 50 years. According to the World Health Organization (White Book on Allergy 2011–2012), allergic rhinitis affects around 30% of the global population.
  • According to the Global Burden of Disease Study, 251 million COPD cases were reported in 2016 and 3.17 million deaths were caused due to the disease in 2015. Therefore, there is a need of early diagnosis and treatment of the disease.

Focus on Geographic Expansion

  • Most respiratory disorder-related deaths occur in low- and lower-middle income countries. High prevalence of respiratory diseases, increase in availability of quality health care services, and growth of the pharmaceutical industry in emerging economies across the globe are creating lucrative opportunities in the respiratory disorders treatment market in these countries.
  • China and Japan are likely to present significant opportunities in the market due to the presence of leading players. In November 2015, F. Hoffmann-La Roche Ltd. opened its new pharmaceutical manufacturing center in Shanghai, China.
  • Rapid adoption of emerging technologies and surge in innovation are the other important aspects that present opportunities in the respiratory disorders treatment market. Moreover, rapid growth and development of the pharmaceutical industry, rise in availability of branded drugs, and increase of burden of respiratory diseases augment the respiratory disorders treatment market.

Patent Expiry of Branded Products and Availability of Generic Equivalents to Hamper Global Respiratory Disorders Treatment Market

  • Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by the patent holder. Patent expiry of branded drugs has a significant impact on the pharmaceutical industry. Patent expiry hampers the revenue generated from the sale of branded drugs and can affect the market share of a company.
  • A few players in the respiratory disorders treatment market face the threat of patient expiry, which increases the availability of generic versions of drugs and create pricing pressure on the manufacturers
  • For instance, AstraZeneca’s Symbicort Turbuhaler went off patent in Europe in 2019, while patents of GlaxoSmithKline plc’s Qvar, Singulair, and Diskus have expired. This is likely to lead to dramatic losses in sales, thereby affecting positions of the companies in the global respiratory disorders treatment market.

Respiratory Disorders Treatment Market: Competition Landscape

  • This report profiles major players in the global respiratory disorders treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global respiratory disorders treatment market is less fragmented, with the presence of large number of international as well as regional players
  • Leading players operating in the global respiratory disorders treatment market are 
    • Mylan N.V
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Sanofi
    • Sunovion Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries
    • CHIESI Farmaceutici S.p.A.
    • Cipla
    • Vertex Pharmaceuticals Incorporated. 
  • These players account for over 50% share of the global market.

Respiratory Disorders Treatment Market: Key Developments

  • Key players in the global respiratory disorders treatment market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies of key players are likely to fuel the growth of the global respiratory disorders treatment market. A few expansion strategies adopted by players operating in the respiratory disorders treatment market are:
    • In September 2019, GlaxoSmithKline plc announced the U.S. Food and Drug Administration (FDA) approval for its biologics Nucala (mepolizumab) for the treatment of severe eosinophilic asthma in children aged between 6 and 11. This approval has extended the add-on treatment for severe eosinophilic asthma in the U.S. for patients between 6 and 11.
    • In July 2019, AstraZeneca received positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to use Fasenra (benralizumab) in pre-filled, single-use auto-injector (the Fasenra pen). This enabled doctors to treat several patients suffering from severe eosinophilic asthma with biologics.
    • In April 2019, Boehringer Ingelheim International GmbH invested EUR 105 Mn to expand its production sites in Dortmund and Ingelheim in Germany for development of respiratory pipeline products. This investment and expansion would boost the production capacity of next-gen inhaler Respimat in Europe.
  • The report on the global respiratory disorders treatment market discussed individual strategies, followed by company profiles of manufacturers of respiratory disorders treatment products. The competitive landscape section has been included in the respiratory disorders treatment market report to provide readers with a dashboard view and a company market share analysis of key players operating in the global respiratory disorders treatment market.

Respiratory Disorders Treatment Market – Scope of the Report

Report on the global respiratory disorders treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides revenue of the global respiratory disorders treatment market for the period from 2017 to 2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global respiratory disorders treatment market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global respiratory disorders treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global respiratory disorders treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global respiratory disorders treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global respiratory disorders treatment market.

The report delves into the competitive landscape of the global respiratory disorders treatment market. Key players operating in the global respiratory disorders treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global respiratory disorders treatment market that have been profiled in this report.

Key Questions Answered in Respiratory Disorders Treatment Market Report

  • What is the scope of growth of combination drugs in the global respiratory disorders treatment market?
  • What will be the Y-o-Y growth of the global respiratory disorders treatment market between 2019 and 2027?
  • What is the influence of changing trends in target therapies on the global respiratory disorders treatment market?
  • Will North America continue to be the most profitable regional market for respiratory disorders treatment providers?
  • Which factors are anticipated to hamper the growth of the global respiratory disorders treatment market during the forecast period?
  • Which are the leading companies in the global respiratory disorders treatment market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global respiratory disorders treatment market. This research methodology is a combination of primary and secondary researches, which helps analysts to warrant the accuracy and reliability of the drawn conclusions.

For more information about this report visit: Respiratory Disorders Treatment Market

Secondary methods referred to by analysts during the production of the global respiratory disorders treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the respiratory disorders treatment market.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the respiratory disorders treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global respiratory disorders treatment market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future projection of the global respiratory disorders treatment market more reliably and accurately.

Related Posts:

Aircraft Hydraulic System Market
Unmanned Ground Vehicle Market
Aircraft Electrical Systems Market
Ground Handling Software Market
Drone Software Market

Leave a Reply

Your email address will not be published.